Science

At Enanta, we are committed to creating important, novel medicines by pursuing bold ideas, employing rigorous research, and striving for scientific excellence in everything we do. We are fortunate to have some of the best and brightest minds across pharma and biotech working at Enanta. We are passionate about science and dedicated to discovering and developing highly differentiated therapeutics through innovative chemistry to treat diseases in areas of high unmet need. These efforts have resulted in developing drugs for combination regimens that have cured hundreds of thousands of people with chronic hepatitis C virus infection. It’s incredibly rewarding for our scientific expertise to have such an impact on patient lives, and this drives us to do it again in other disease areas.

As part of our drug discovery efforts, we have published several posters, presentations and manuscripts highlighting the depth of our scientific expertise. To review our literature, please see below.

Publications

Filter by Program

RSV: Zelicapavir
RSV: EDP-323
COVID-19: EDP-235
HBV: EDP-514
NASH: EDP-305
NASH: EDP-297
Other

Filter by Format

Poster
Presentation
Publication
Slides
Date
Source
Title
Program
Format
image for EDP-323 Challenge Study Topline Data Results Call
September 26, 2024
Enanta.com
EDP-323 Challenge Study Topline Data Results Call
RSV: EDP-323
Slides
image for The Small Molecule Inhibitor of SARS-CoV-2 3CLpro EDP-235 Prevents Viral Replication and Transmission in Vivo
August 1, 2024
Nature Communications
The Small Molecule Inhibitor of SARS-CoV-2 3CLpro EDP-235 Prevents Viral Replication and Transmission in Vivo
COVID-19: EDP-235
Publication
image for Efficacy and Safety of EDP-235 in Nonhospitalized Adults With Mild or Moderate COVID-19: Results From the Phase 2 SPRINT Study
April 27, 2024
ESCMID Global 2024
Efficacy and Safety of EDP-235 in Nonhospitalized Adults With Mild or Moderate COVID-19: Results From the Phase 2 SPRINT Study
COVID-19: EDP-235
Poster
image for Phase 1 Trial of the Safety, Pharmacokinetics, and Antiviral Activity of EDP-514 in Untreated Viremic Chronic Hepatitis B Patients
March 26, 2024
Clinical and Molecular Hepatology
Phase 1 Trial of the Safety, Pharmacokinetics, and Antiviral Activity of EDP-514 in Untreated Viremic Chronic Hepatitis B Patients
HBV: EDP-514
Publication
image for EDP-938, A Respiratory Syncytial Virus Antiviral, Demonstrates a High Barrier to Resistance in a Human Challenge Study
October 12, 2023
IDWeek 2023
EDP-938, A Respiratory Syncytial Virus Antiviral, Demonstrates a High Barrier to Resistance in a Human Challenge Study
RSV: Zelicapavir
Poster
image for EDP-323, a First-in-Class, Once-Daily, Oral L-Protein Inhibitor for the Treatment of RSV: Results from a Phase 1 Study in Healthy Subjects and Correlation with In Vitro Antiviral Activity
September 18, 2023
9th ESWI Influenza Conference
EDP-323, a First-in-Class, Once-Daily, Oral L-Protein Inhibitor for the Treatment of RSV: Results from a Phase 1 Study in Healthy Subjects and Correlation with In Vitro Antiviral Activity
RSV: EDP-323
Poster
image for HSD17B13 Inhibitors are Hepatoprotective and Anti-inflammatory in a Mouse Model of Autoimmune Hepatitis
June 23, 2023
EASL 2023
HSD17B13 Inhibitors are Hepatoprotective and Anti-inflammatory in a Mouse Model of Autoimmune Hepatitis
Other
Poster
image for SPRINT Phase 2 Study of EDP-235: Topline Results & Additional Analyses
June 8, 2023
Enanta.com
SPRINT Phase 2 Study of EDP-235: Topline Results & Additional Analyses
COVID-19: EDP-235
Slides
image for Pharmacokinetics of EDP-323, a Potent, Once-Daily, Oral Antiviral Treatment for Respiratory Syncytial Virus
April 17, 2023
ECCMID 2023
Pharmacokinetics of EDP-323, a Potent, Once-Daily, Oral Antiviral Treatment for Respiratory Syncytial Virus
RSV: EDP-323
Poster
image for EDP-235, a Potent, Once-Daily, Oral Antiviral, Demonstrates Potential for Treatment and Prevention of Long COVID
April 17, 2023
ECCMID 2023
EDP-235, a Potent, Once-Daily, Oral Antiviral, Demonstrates Potential for Treatment and Prevention of Long COVID
COVID-19: EDP-235
Poster
image for EDP-235, an Oral 3CL Protease Inhibitor for the Treatment of COVID-19, Suppresses Viral Replication and Transmission in SARS-CoV-2-Infected Ferrets
March 15, 2023
ICAR 2023
EDP-235, an Oral 3CL Protease Inhibitor for the Treatment of COVID-19, Suppresses Viral Replication and Transmission in SARS-CoV-2-Infected Ferrets
COVID-19: EDP-235
Presentation
image for High Throughput Screen to Identify Non-Nucleoside Small Molecule Inhibitors of SARS-CoV-2 RNA-Dependent RNA Polymerase
March 14, 2023
ICAR 2023
High Throughput Screen to Identify Non-Nucleoside Small Molecule Inhibitors of SARS-CoV-2 RNA-Dependent RNA Polymerase
COVID-19: EDP-235
Poster
image for EDP-235, a Potent, Once-daily, Oral Antiviral, Demonstrates Excellent Penetration into SARS-CoV-2 Target Tissues, with the Potential for Mitigation of Viral Rebound in COVID-19 Patients
March 14, 2023
ICAR 2023
EDP-235, a Potent, Once-daily, Oral Antiviral, Demonstrates Excellent Penetration into SARS-CoV-2 Target Tissues, with the Potential for Mitigation of Viral Rebound in COVID-19 Patients
COVID-19: EDP-235
Poster
image for EDP-235, an Oral, Once Daily, Ritonavir-Free, 3CL Protease Inhibitor for the Treatment of COVID-19: Results from Phase 1 Study in Healthy Subjects
March 14, 2023
ICAR 2023
EDP-235, an Oral, Once Daily, Ritonavir-Free, 3CL Protease Inhibitor for the Treatment of COVID-19: Results from Phase 1 Study in Healthy Subjects
COVID-19: EDP-235
Poster
image for Discovery and Characterization of Hydroxysteroid 17-β Dehydrogenase 13 Inhibitors
November 4, 2022
AASLD 2022
Discovery and Characterization of Hydroxysteroid 17-β Dehydrogenase 13 Inhibitors
Other
Poster
image for Characterization of Mouse and Human HSD17B13 Structure and Activity
November 4, 2022
AASLD 2022
Characterization of Mouse and Human HSD17B13 Structure and Activity
Other
Poster
image for EDP-235, a Potent and Once-Daily Oral Antiviral, Demonstrates Excellent Penetration into Macrophages and Monocytes with the Potential for Mitigation of Cytokine Storm in COVID-19 Patients
October 21, 2022
IDWeek 2022
EDP-235, a Potent and Once-Daily Oral Antiviral, Demonstrates Excellent Penetration into Macrophages and Monocytes with the Potential for Mitigation of Cytokine Storm in COVID-19 Patients
COVID-19: EDP-235
Presentation
image for EDP-235, a Potent and Once-Daily Oral Antiviral, Demonstrates Excellent Penetration into Macrophages and Monocytes with the Potential for Mitigation of Cytokine Storm in COVID-19 Patients
October 21, 2022
IDWeek 2022
EDP-235, a Potent and Once-Daily Oral Antiviral, Demonstrates Excellent Penetration into Macrophages and Monocytes with the Potential for Mitigation of Cytokine Storm in COVID-19 Patients
COVID-19: EDP-235
Poster
image for EDP-235, a Potent, Once-Daily Oral Antiviral Treatment for COVID-19
October 20, 2022
Discovery on Target 2022
EDP-235, a Potent, Once-Daily Oral Antiviral Treatment for COVID-19
COVID-19: EDP-235
Presentation
image for EDP-323, a Small Molecule L-Protein Inhibitor, in Development Against Respiratory Syncytial Virus
October 19, 2022
Discovery on Target 2022
EDP-323, a Small Molecule L-Protein Inhibitor, in Development Against Respiratory Syncytial Virus
RSV: EDP-323
Presentation
image for EDP-323, a Novel L-Protein Inhibitor, for the Treatment of Respiratory Syncytial Virus
October 1, 2022
12th International RSV Symposium
EDP-323, a Novel L-Protein Inhibitor, for the Treatment of Respiratory Syncytial Virus
RSV: EDP-323
Presentation
image for In Vivo Efficacy of EDP-323, a Novel L-Protein Inhibitor, for the Treatment of Respiratory Syncytial Virus
September 30, 2022
12th International RSV Symposium
In Vivo Efficacy of EDP-323, a Novel L-Protein Inhibitor, for the Treatment of Respiratory Syncytial Virus
RSV: EDP-323
Poster
image for An Improved Toolkit for In Vitro hMPV Characterization
September 30, 2022
12th International RSV Symposium
An Improved Toolkit for In Vitro hMPV Characterization
Other
Poster
image for Evaluation of a Human 3D Airway Tissue Culture Model for the Study of Respiratory Syncytial Virus Infection and the Development of Antiviral Drugs
September 30, 2022
12th International RSV Symposium
Evaluation of a Human 3D Airway Tissue Culture Model for the Study of Respiratory Syncytial Virus Infection and the Development of Antiviral Drugs
RSV: Zelicapavir
Poster
image for EDP-514, a Novel Pangenotypic Class II Hepatitis B Virus Core Inhibitor: Results of a 28-day Phase 1b Study in NUC suppressed CHB Patients
June 25, 2022
EASL 2022
EDP-514, a Novel Pangenotypic Class II Hepatitis B Virus Core Inhibitor: Results of a 28-day Phase 1b Study in NUC suppressed CHB Patients
HBV: EDP-514
Poster
image for EDP-514, a Novel Pangenotypic Class II Hepatitis B Virus Core Inhibitor Demonstrates Significant HBV DNA and HBV RNA Reductions in a Phase 1b Study in Viremic, Chronic Hepatitis B Infected Patients
June 25, 2022
EASL 2022
EDP-514, a Novel Pangenotypic Class II Hepatitis B Virus Core Inhibitor Demonstrates Significant HBV DNA and HBV RNA Reductions in a Phase 1b Study in Viremic, Chronic Hepatitis B Infected Patients
HBV: EDP-514
Poster
image for EDP-297: A Novel, Highly Potent, Farnesoid X Receptor Agonist: Results of a Phase 1 Study in Healthy Subjects
June 25, 2022
EASL 2022
EDP-297: A Novel, Highly Potent, Farnesoid X Receptor Agonist: Results of a Phase 1 Study in Healthy Subjects
NASH: EDP-297
Poster
image for Pharmacological Inhibition of HSD17B13 Is Hepatoprotective In Mouse Models of Liver Injury
June 25, 2022
EASL 2022
Pharmacological Inhibition of HSD17B13 Is Hepatoprotective In Mouse Models of Liver Injury
Other
Poster
image for Molecular Basis for the Antiviral Action of EDP-235: A Potent and Selective SARS-CoV-2 3CLpro Inhibitor
April 4, 2022
Experimental Biology 2022
Molecular Basis for the Antiviral Action of EDP-235: A Potent and Selective SARS-CoV-2 3CLpro Inhibitor
COVID-19: EDP-235
Presentation
image for Molecular Basis for the Antiviral Action of EDP-235: A Potent and Selective SARS-CoV-2 3CLpro Inhibitor for the Treatment of COVID-19
April 4, 2022
Experimental Biology 2022
Molecular Basis for the Antiviral Action of EDP-235: A Potent and Selective SARS-CoV-2 3CLpro Inhibitor for the Treatment of COVID-19
COVID-19: EDP-235
Poster
image for EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge
February 17, 2022
The New England Journal of Medicine
EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge
RSV: Zelicapavir
Publication
image for Phase 1 Study of EDP-305, a Novel Once-Daily Oral Farnesoid X Receptor Agonist, in Healthy Subjects and Those with Presumptive Nonalcoholic Fatty Liver Disease
November 17, 2021
International Journal of Gastroenterology
Phase 1 Study of EDP-305, a Novel Once-Daily Oral Farnesoid X Receptor Agonist, in Healthy Subjects and Those with Presumptive Nonalcoholic Fatty Liver Disease
NASH: EDP-305
Publication
image for EDP-514, a Novel Pangeonotypic Class II Hepatitis B Virus Core Inhibitor: Preliminary Results of a 28-Day Phase 1b Study in NUC-Suppressed CHB Patients 
November 12, 2021
AASLD 2021
EDP-514, a Novel Pangeonotypic Class II Hepatitis B Virus Core Inhibitor: Preliminary Results of a 28-Day Phase 1b Study in NUC-Suppressed CHB Patients 
HBV: EDP-514
Poster
image for EDP-514, a Potent Pangenotypic Class II Hepatitis B Virus Core Inhibitor, Demonstrates Significant HBV DNA and HBV RNA Reductions in a Phase 1b Study in Viremic, Chronic Hepatitis B Infected Patients  
November 12, 2021
AASLD 2021
EDP-514, a Potent Pangenotypic Class II Hepatitis B Virus Core Inhibitor, Demonstrates Significant HBV DNA and HBV RNA Reductions in a Phase 1b Study in Viremic, Chronic Hepatitis B Infected Patients  
HBV: EDP-514
Poster
image for EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study
November 3, 2021
Journal of Hepatology
EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study
NASH: EDP-305
Publication
image for EDP-235, A Potential Oral, Once-Daily Antiviral Treatment and Preventative for COVID-19
October 19, 2021
ISIRV WHO Virtual Conference 2021
EDP-235, A Potential Oral, Once-Daily Antiviral Treatment and Preventative for COVID-19
COVID-19: EDP-235
Poster
image for Mechanism and structural basis of small molecule inhibition of PAPD5 and PAPD7
September 27, 2021
HBV International Meeting
Mechanism and structural basis of small molecule inhibition of PAPD5 and PAPD7
Other
Presentation
image for Discovery and Characterization of EDP-721, a Novel Hepatitis B Virus RNA Destabilizer
June 23, 2021
EASL 2021
Discovery and Characterization of EDP-721, a Novel Hepatitis B Virus RNA Destabilizer
Other
Poster
image for EDP-938, a Novel Nucleoprotein Inhibitor of Respiratory Syncytial Virus, Demonstrates Potent Antiviral Activities In Vitro and in a Nonhuman Primate Model
March 15, 2021
PLOS Pathogens
EDP-938, a Novel Nucleoprotein Inhibitor of Respiratory Syncytial Virus, Demonstrates Potent Antiviral Activities In Vitro and in a Nonhuman Primate Model
RSV: Zelicapavir
Publication
image for EDP-514, a Novel Pan genotypic Class II Hepatitis B Virus Core Inhibitor: Final Results of a Phase 1 Study in Healthy Adult Subjects
August 29, 2020
EASL 2020
EDP-514, a Novel Pan genotypic Class II Hepatitis B Virus Core Inhibitor: Final Results of a Phase 1 Study in Healthy Adult Subjects
HBV: EDP-514
Poster
image for A Phase 2 Dose Ranging, Randomized, Double-blind and Placebo-Controlled Study of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis
August 29, 2020
EASL 2020
A Phase 2 Dose Ranging, Randomized, Double-blind and Placebo-Controlled Study of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis
NASH: EDP-305
Presentation
image for A Novel FXR Agonist EDP-297 Exerts Anti-Inflammatory and Hepatoprotective Effects in Human Liver 3D Microtissues and in Rodent Models of Liver Injury and NASH
August 29, 2020
EASL 2020
A Novel FXR Agonist EDP-297 Exerts Anti-Inflammatory and Hepatoprotective Effects in Human Liver 3D Microtissues and in Rodent Models of Liver Injury and NASH
NASH: EDP-297
Poster
image for EDP-297, A Novel and Potent FXR Agonist, Exhibits Robust Anti-Fibrotic Effects with Significant Liver Function Improvement in a Rat Model of Non-Alcoholic Steatohepatitis
August 28, 2020
EASL 2020
EDP-297, A Novel and Potent FXR Agonist, Exhibits Robust Anti-Fibrotic Effects with Significant Liver Function Improvement in a Rat Model of Non-Alcoholic Steatohepatitis
NASH: EDP-297
Poster
image for Final Data of the Phase 2a INTREPID Study with EDP-305, a Non-Bile Acid Farnesoid X Receptor (FXR) Agonist
May 6, 2020
Enanta.com
Final Data of the Phase 2a INTREPID Study with EDP-305, a Non-Bile Acid Farnesoid X Receptor (FXR) Agonist
Other
Slides
image for A Novel Non-Bile Acid FXR Agonist EDP-305 Potently Suppresses Liver Injury and Fibrosis without Worsening of Ductular Reaction
May 6, 2020
Liver International
A Novel Non-Bile Acid FXR Agonist EDP-305 Potently Suppresses Liver Injury and Fibrosis without Worsening of Ductular Reaction
NASH: EDP-305
Publication
image for The Farnesoid X Receptor Agonist EDP-305 Reduces Interstitial Renal Fibrosis in a Mouse Model of Unilateral Ureteral Obstruction
March 18, 2020
The FASEB Journal
The Farnesoid X Receptor Agonist EDP-305 Reduces Interstitial Renal Fibrosis in a Mouse Model of Unilateral Ureteral Obstruction
NASH: EDP-305
Publication
image for A Novel Non-Bile Acid FXR Agonist EDP-305 Prevents Progression to Cirrhosis in Rats
November 11, 2019
AASLD 2019
A Novel Non-Bile Acid FXR Agonist EDP-305 Prevents Progression to Cirrhosis in Rats
NASH: EDP-305
Poster
image for Decreases in Serum 7-alpha-Hydroxy-4-Cholesten-3-One (C4) Correlate Well with Anti-Fibrotic Efficacy of EDP-305 in Nonalcoholic Steatohepatitis (NASH) and Biliary Fibrosis Animal Models
November 11, 2019
AASLD 2019
Decreases in Serum 7-alpha-Hydroxy-4-Cholesten-3-One (C4) Correlate Well with Anti-Fibrotic Efficacy of EDP-305 in Nonalcoholic Steatohepatitis (NASH) and Biliary Fibrosis Animal Models
NASH: EDP-305
Poster
image for EDP-938, a Novel RSV N-inhibitor, Administered Once or Twice Daily was Safe and Demonstrated Robust Antiviral and Clinical Efficacy in a Healthy Volunteer Challenge Study
October 3, 2019
IDWeek 2019
EDP-938, a Novel RSV N-inhibitor, Administered Once or Twice Daily was Safe and Demonstrated Robust Antiviral and Clinical Efficacy in a Healthy Volunteer Challenge Study
RSV: Zelicapavir
Presentation
image for Preclinical Pharmacokinetic and Pharmacodynamic Characterization of EDP-938, a Novel and Potent Non-Fusion Replication Inhibitor of Respiratory Syncytial Virus (RSV)
October 2, 2019
IDWeek 2019
Preclinical Pharmacokinetic and Pharmacodynamic Characterization of EDP-938, a Novel and Potent Non-Fusion Replication Inhibitor of Respiratory Syncytial Virus (RSV)
RSV: Zelicapavir
Poster
image for A Phase 2 Dose Ranging, Randomized, Double-blind and Placebo-Controlled Study of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis
September 25, 2019
Enanta.com
A Phase 2 Dose Ranging, Randomized, Double-blind and Placebo-Controlled Study of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis
NASH: EDP-305
Slides
image for Tissue distribution of EDP-305, a highly selective and potent farnesoid X receptor (FXR) agonist, in preclinical species
July 28, 2019
ISSX 2019
Tissue distribution of EDP-305, a highly selective and potent farnesoid X receptor (FXR) agonist, in preclinical species
NASH: EDP-305
Poster
image for EDP 938-101 Phase 2a Study: Human Challenge Study
June 14, 2019
Enanta.com
EDP 938-101 Phase 2a Study: Human Challenge Study
RSV: Zelicapavir
Slides
image for EDP-305, a Highly Selective and Potent FXR Agonist, Reduces Liver Steatosis, Ballooning, and Non-Alcoholic Fatty Liver Disease Activity Score (NAS) in Two Murine Models of NASH
June 4, 2019
NASH TAG 2019
EDP-305, a Highly Selective and Potent FXR Agonist, Reduces Liver Steatosis, Ballooning, and Non-Alcoholic Fatty Liver Disease Activity Score (NAS) in Two Murine Models of NASH
NASH: EDP-305
Presentation
image for Characterization of EDP-305, a Highly Potent and Selective Farnesoid X Receptor Agonist, for the Treatment of Non-alcoholic Steatohepatitis
June 1, 2019
International Journal of Gastroenterology
Characterization of EDP-305, a Highly Potent and Selective Farnesoid X Receptor Agonist, for the Treatment of Non-alcoholic Steatohepatitis
NASH: EDP-305
Publication
image for EDP-514, a Novel HBV Core Inhibitor with Potent Antiviral Activity both In Vitro and In Vivo
April 12, 2019
EASL 2019
EDP-514, a Novel HBV Core Inhibitor with Potent Antiviral Activity both In Vitro and In Vivo
HBV: EDP-514
Poster
image for A Comparative Study of Fibrosis Treatments using Aptamer-Based Quantitative Proteomics in a Model of Nonalcoholic Steatohepatitis Cirrhosis
April 12, 2019
EASL 2019
A Comparative Study of Fibrosis Treatments using Aptamer-Based Quantitative Proteomics in a Model of Nonalcoholic Steatohepatitis Cirrhosis
NASH: EDP-305
Poster
image for In Vivo Effects of a Novel Inhibitor of Apoptosis Signal-Regulating Kinase 1 (ASK1) in Mouse Models of Liver Injury and Metabolic Disease
April 12, 2019
EASL 2019
In Vivo Effects of a Novel Inhibitor of Apoptosis Signal-Regulating Kinase 1 (ASK1) in Mouse Models of Liver Injury and Metabolic Disease
NASH: EDP-305
Poster
image for Discovery and Development of Novel and Potent Non-Fusion Inhibitors of RSV
November 29, 2018
RESPIDart
Discovery and Development of Novel and Potent Non-Fusion Inhibitors of RSV
RSV: Zelicapavir
Presentation
image for The Farnesoid X Receptor (FXR) Agonist EDP-305 Inhibits Fibrosis Progression in a Rat Model of Nonalcoholic Steatohepatitis Cirrhosis
November 9, 2018
AASLD 2018
The Farnesoid X Receptor (FXR) Agonist EDP-305 Inhibits Fibrosis Progression in a Rat Model of Nonalcoholic Steatohepatitis Cirrhosis
NASH: EDP-305
Poster
image for The Farnesoid X Receptor (FXR) Agonist EDP-305 Reduces Ascites and Hepatocellular Carcinoma Development in a Rat Model of Cirrhosis
November 9, 2018
AASLD 2018
The Farnesoid X Receptor (FXR) Agonist EDP-305 Reduces Ascites and Hepatocellular Carcinoma Development in a Rat Model of Cirrhosis
NASH: EDP-305
Poster
image for The Farnesoid X Receptor (FXR) Agonist EDP-305 Reduces Interstitial Renal Fibrosis in a Mouse Model of Unilateral Ureteral Obstruction
November 5, 2018
Kidney Week 2018
The Farnesoid X Receptor (FXR) Agonist EDP-305 Reduces Interstitial Renal Fibrosis in a Mouse Model of Unilateral Ureteral Obstruction
NASH: EDP-305
Poster
image for EDP-938, a Novel, Non-Fusion Replication Inhibitor of Respiratory Syncytial Virus: Preliminary Results of a Phase 1 Study in Healthy Subjects
November 2, 2018
RSV 2018
EDP-938, a Novel, Non-Fusion Replication Inhibitor of Respiratory Syncytial Virus: Preliminary Results of a Phase 1 Study in Healthy Subjects
RSV: Zelicapavir
Poster
image for EDP-938, a Novel Non-Fusion Replication Inhibitor of RSV, Displays a High Barrier to Resistance In Vitro
November 2, 2018
RSV 2018
EDP-938, a Novel Non-Fusion Replication Inhibitor of RSV, Displays a High Barrier to Resistance In Vitro
RSV: Zelicapavir
Presentation
image for Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety/Tolerability Effects of EDP-305, a Novel Once-Daily Oral Farnesoid X Receptor (FXR) Agonist in Healthy Subjects and in Subjects with Presumptive Nonalcoholic Fatty Liver Disease (NAFLD)
June 4, 2018
NASH TAG 2018
Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety/Tolerability Effects of EDP-305, a Novel Once-Daily Oral Farnesoid X Receptor (FXR) Agonist in Healthy Subjects and in Subjects with Presumptive Nonalcoholic Fatty Liver Disease (NAFLD)
NASH: EDP-305
Poster
image for EDP-305, a highly selective and potent FXR agonist, reduces liver steatosis, ballooning, and non-alcoholic fatty liver disease activity score(NAS) in two murine models of NASH
June 2, 2018
DDW 2018
EDP-305, a highly selective and potent FXR agonist, reduces liver steatosis, ballooning, and non-alcoholic fatty liver disease activity score(NAS) in two murine models of NASH
NASH: EDP-305
Poster
image for EDP-305, a Potent and Selective Farnesoid X Receptor Agonist, Exhibits Anti-fibrotic Effect In Vitro
June 2, 2018
DDW 2018
EDP-305, a Potent and Selective Farnesoid X Receptor Agonist, Exhibits Anti-fibrotic Effect In Vitro
NASH: EDP-305
Poster
image for EDP-305 Favorably Regulates Lipoprotein Mechanism In Vitro and In Vivo 
June 2, 2018
DDW 2018
EDP-305 Favorably Regulates Lipoprotein Mechanism In Vitro and In Vivo 
NASH: EDP-305
Poster
image for Molecular Magnetic Resonance Imaging Accurately Measures the Antifibrotic Effect of EDP-305, a Novel Farnesoid X Receptor Agonist
May 21, 2018
Hepatology Communications
Molecular Magnetic Resonance Imaging Accurately Measures the Antifibrotic Effect of EDP-305, a Novel Farnesoid X Receptor Agonist
NASH: EDP-305
Publication
image for Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety/Tolerability Effects of EDP-305, a Novel Once-Daily Oral Farnesoid X Receptor (FXR) Agonist in Healthy Subjects and in Subjects with Presumptive Nonalcoholic Fatty Liver Disease
April 13, 2018
EASL 2018
Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety/Tolerability Effects of EDP-305, a Novel Once-Daily Oral Farnesoid X Receptor (FXR) Agonist in Healthy Subjects and in Subjects with Presumptive Nonalcoholic Fatty Liver Disease
NASH: EDP-305
Poster
image for EDP-305, A Highly Selective and Potent Farnesoid X Receptor Agonist, Favorably Regulates the Expression of Key Fibrogenic Genes In Vitro and In Vivo
April 13, 2018
EASL 2018
EDP-305, A Highly Selective and Potent Farnesoid X Receptor Agonist, Favorably Regulates the Expression of Key Fibrogenic Genes In Vitro and In Vivo
NASH: EDP-305
Poster
image for EDP-305 Modulates Lipoprotein Metabolism Via Distinct Chromatin and miRNA Regulatory Mechanisms
April 12, 2018
EASL 2018
EDP-305 Modulates Lipoprotein Metabolism Via Distinct Chromatin and miRNA Regulatory Mechanisms
NASH: EDP-305
Poster
image for Significant Anti-Fibrotic Efficacy of EDP-305, a Highly Potent and Selective Farnesoid X Receptor (FXR) Agonist, in a Rat Model of Thioacetamide Induced Liver Fibrosis and Cirrhosis
October 20, 2017
AASLD 2017
Significant Anti-Fibrotic Efficacy of EDP-305, a Highly Potent and Selective Farnesoid X Receptor (FXR) Agonist, in a Rat Model of Thioacetamide Induced Liver Fibrosis and Cirrhosis
NASH: EDP-305
Presentation
image for EDP-305 Favorably Regulates Lipoprotein Mechanism In Vitro
October 20, 2017
AASLD 2017
EDP-305 Favorably Regulates Lipoprotein Mechanism In Vitro
NASH: EDP-305
Poster
image for A Novel FXR Agonist EDP-305 Potently Suppresses Hepatic Stellate Cell Activation and Hepatic Fibrosis in Chronic Mouse Models of Biliary and Betabolic Liver Disease
October 20, 2017
AASLD 2017
A Novel FXR Agonist EDP-305 Potently Suppresses Hepatic Stellate Cell Activation and Hepatic Fibrosis in Chronic Mouse Models of Biliary and Betabolic Liver Disease
NASH: EDP-305
Poster
image for EDP-938, a Novel Non-Fusion Replication Inhibitor of Respiratory Syncytial Virus, Demonstrates Potent Antiviral Activities both In Vitro and In Vivo
June 25, 2017
RSV 2017
EDP-938, a Novel Non-Fusion Replication Inhibitor of Respiratory Syncytial Virus, Demonstrates Potent Antiviral Activities both In Vitro and In Vivo
RSV: Zelicapavir
Presentation
image for A Novel and Highly Potent FXR Agonist EDP-305 Decreases Liver Steatosis, Ballooning, and NAS Score in a Diet-Induced Murine Model of Non-Alcoholic Steatohepatitis (NASH)
April 19, 2017
EASL 2017
A Novel and Highly Potent FXR Agonist EDP-305 Decreases Liver Steatosis, Ballooning, and NAS Score in a Diet-Induced Murine Model of Non-Alcoholic Steatohepatitis (NASH)
NASH: EDP-305
Poster
image for A Novel FXR Agonist EDP-305 Potently Suppresses Liver Injury and Fibrosis in Mouse Models of Biliary and Metabolic Liver Disease
April 19, 2017
EASL 2017
A Novel FXR Agonist EDP-305 Potently Suppresses Liver Injury and Fibrosis in Mouse Models of Biliary and Metabolic Liver Disease
NASH: EDP-305
Poster
image for The Novel FXR Agonist, EDP-305, Reduces Fibrosis Progression in Rodent Models of Primary Biliary Cholangitis and Non-alcoholic Steatohepatitis
April 19, 2017
EASL 2017
The Novel FXR Agonist, EDP-305, Reduces Fibrosis Progression in Rodent Models of Primary Biliary Cholangitis and Non-alcoholic Steatohepatitis
NASH: EDP-305
Poster
image for A Novel and Highly Potent FXR Agonist EDP-305 Suppresses Liver Injury and Fibrosis in a Murine Model of Steatohepatitis
January 5, 2017
NASH TAG 2017
A Novel and Highly Potent FXR Agonist EDP-305 Suppresses Liver Injury and Fibrosis in a Murine Model of Steatohepatitis
NASH: EDP-305
Presentation
image for EP-024297, A Novel and Selective Farnesoid X Receptor Agonist, Exhibits High Potency and Efficacy In Vitro and In Vivo
November 13, 2016
AASLD 2016
EP-024297, A Novel and Selective Farnesoid X Receptor Agonist, Exhibits High Potency and Efficacy In Vitro and In Vivo
NASH: EDP-297
Poster
image for EDP-305, A Novel and Selective Farnesoid X Receptor Agonist Exhibits Excellent Potency and Efficacy In Vitro and In Vivo
November 13, 2016
AASLD 2016
EDP-305, A Novel and Selective Farnesoid X Receptor Agonist Exhibits Excellent Potency and Efficacy In Vitro and In Vivo
NASH: EDP-305
Poster
image for EDP-305, A Novel and Highly Potent Farnesoid X Receptor Agonist, Exerts Favorable Effects on Lipid Metabolism In Vitro
November 13, 2016
AASLD 2016
EDP-305, A Novel and Highly Potent Farnesoid X Receptor Agonist, Exerts Favorable Effects on Lipid Metabolism In Vitro
NASH: EDP-305
Poster
image for EDP-305, A Novel and Potent Farnesoid X Receptor Agonist, Exhibits Excellent Anti-Inflammatory and Anti-fibrotic Activity In Vitro
November 13, 2016
AASLD 2016
EDP-305, A Novel and Potent Farnesoid X Receptor Agonist, Exhibits Excellent Anti-Inflammatory and Anti-fibrotic Activity In Vitro
NASH: EDP-305
Poster
image for The Novel FXR Agonist, EDP-305, Reduces Fibrosis Progression in Rodent Models of Primary Biliary Cholangitis and Non-alcoholic Steatohepatitis
November 11, 2016
AASLD 2016
The Novel FXR Agonist, EDP-305, Reduces Fibrosis Progression in Rodent Models of Primary Biliary Cholangitis and Non-alcoholic Steatohepatitis
NASH: EDP-305
Poster
image for EP-023938, A Novel Non-Fusion Replication Inhibitor of Respiratory Syncytial Virus
September 8, 2016
RSV 2016
EP-023938, A Novel Non-Fusion Replication Inhibitor of Respiratory Syncytial Virus
RSV: Zelicapavir
Poster
MENU